US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam

World News: . []

LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today reports on the favourable outcome of a decision by the US PTAB against Alnylam.

In the US, Alnylam filed a total of five Post Grant Review (PGR) petitions against newly-issued Silence patents challenging the validity of the issued claims. In the first decision on Alnylam’s petitions, the PTAB denied institution of post-grant review, finding that Alnylam had not met its initial burden of showing that the claims are invalid.

The PTAB’s decision not to institute review provides yet another vindication of the strength of Silence’s worldwide patent portfolio.

Decisions on the remaining petitions are expected over the next several months.

“We are very pleased with this favourable outcome in US patent office proceedings initiated by Alnylam. We are hopeful that the remaining proceedings will result in similar outcomes and that Silence’s patent position will be fully vindicated.”

More news and information about Silence Therapeutics plc

Published By:

Globe Newswire: 15:07 GMT Friday 12th October 2018

Published: .

Search for other references to "patent" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us